Table 1 Baseline demographic and medical characteristics for the triptans and control groups before and after propensity score matching

Baseline characteristics

Female sex, No.(%)

33,809 (71.4)

135,236 (71.4)

18,367 (74.1)

72,996 (73.7)

Age, mean (SD)

71.7 (6)

71.7 (6)

71.6 (6)

71.5 (6)

Comorbididity, No.(%)

 Hypertension

25,540 (53.9)

120,848 (63.8)

18,495 (74.5)

74,296 (75)

 Cardiovascular diseases

12,148 (25.7)

74,334 (39.2)

11,818 (47.7)

47,629 (48.1)

  Myocardial infarction

393 (0.83)

3557 (1.88)

393 (1.59)

1912 (1.93)

  Cardiac failure

600 (1.27)

5392 (2.85)

624 (2.52)

2672 (2.70)

  Peripheral disease

893 (1.88)

6939 (3.66)

857 (3.45)

3703 (3.74)

  Cerebrovascular disease

994 (2.1))

6832 (3.61)

897 (3.62)

3688 (3.72)

 Dyslipidemia

17,561 (37.1)

83,076 (43.9)

12,314 (49.7)

49,077 (49.5)

 Diabetes

5616 (11.9)

38,638 (20.4)

5764 (23.3)

23,191 (23.4)

Charlson comorbidity index No.(%)

 0

35,934 (75.9)

124,232 (65.5)

14,645 (59.1)

58,427 (59)

 ≤ 2

9798 (20.7)

50,964 (26.9)

8453 (34.1)

34,160 (34.5)

 3–4

1235 (2.6)

9557 (5.1)

1259 (5.1)

4970 (5)

 ≥ 5

386 (0.8)

4659 (2.5)

417 (1.7)

1539 (1.6)

Number of hospitalisations, days, mean (SD)

0.9 (5)

2.4 (9.8)

1.7 (7)

2.1 (9)

Number of medical visits, mean (SD)

5.5 (5.0)

6.0 (5.2)

6.5 (5.2)

6.3 (4.9)